The abstract is read at the publisher; the summary is JClub's.
Quantitative plaque analysis using coronary computed tomography angiography (CCTA) is discussed as a potential screening approach in asymptomatic adults, but current evidence is not yet sufficient to support clinical use for guiding therapy.
- Why it matters: The gap is whether existing CCTA plaque quantification data can justify using it as a screening tool to inform treatment decisions in people without symptoms.
- What they did: The Viewpoint reviews how CCTA enables quantitative plaque analysis and evaluates whether current findings align with clinical screening needs in asymptomatic adults.
- The result: The discussion concludes that current data do not adequately support CCTA plaque analysis for clinical screening to guide therapy in asymptomatic adults.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.